Background: Attainment of therapeutic goals in Type 2 Diabetes Mellitus (T2DM) necessitates the rational use of drugs, given the wide options available and the presence of co-morbid diseases. Objec
The AMASSplus application is an extension of AMASS Version 1.1 that was released on 12 January 2021. AMASSplus has an additional report (page 38-40) on selected notifiable bacterial diseases.For impl